Synaptic neurodegeneration is thought to be an early event initiated by soluble β-amyloid (Aβ) aggregates that closely correlates with cognitive decline in Alzheimer disease (AD). Apolipoprotein ε4 (APOE4) is the most common genetic risk factor for both familial AD (FAD) and sporadic AD; it accelerates Aβ aggregation and selectively impairs glutamate receptor function and synaptic plasticity. However, its molecular mechanisms remain elusive and these synaptic deficits are difficult to monitor. AD-and APOE4-dependent plasma biomarkers have been proposed, but synapse-related plasma biomarkers are lacking. We evaluated neuronal pentraxin 1 (NP1), a potential CNS-derived plasma biomarker of excitatory synaptic pathology. NP1 is preferentially expressed in brain and involved in glutamate receptor internalization. NP1 is secreted presynaptically induced by Aβ oligomers, and implicated in excitatory synaptic and mitochondrial deficits. Levels of NP1 and its fragments were increased in a correlated fashion in both brain and plasma of 7-8 month-old E4FAD mice relative to E3FAD mice. NP1 was also found in exosome preparations and reduced by dietary DHA supplementation. Plasma NP1 was higher in E4FAD+ (APOE4 +/+ /FAD +/− ) relative to E4FAD-(non-carrier; APOE4
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A B S T R A C T
Synaptic neurodegeneration is thought to be an early event initiated by soluble β-amyloid (Aβ) aggregates that closely correlates with cognitive decline in Alzheimer disease (AD). Apolipoprotein ε4 (APOE4) is the most common genetic risk factor for both familial AD (FAD) and sporadic AD; it accelerates Aβ aggregation and selectively impairs glutamate receptor function and synaptic plasticity. However, its molecular mechanisms remain elusive and these synaptic deficits are difficult to monitor. AD-and APOE4-dependent plasma biomarkers have been proposed, but synapse-related plasma biomarkers are lacking. We evaluated neuronal pentraxin 1 (NP1), a potential CNS-derived plasma biomarker of excitatory synaptic pathology. NP1 is preferentially expressed in brain and involved in glutamate receptor internalization. NP1 is secreted presynaptically induced by Aβ oligomers, and implicated in excitatory synaptic and mitochondrial deficits. Levels of NP1 and its fragments were increased in a correlated fashion in both brain and plasma of 7-8 month-old E4FAD mice relative to E3FAD mice. NP1 was also found in exosome preparations and reduced by dietary DHA supplementation. Plasma NP1 was higher in E4FAD+ (APOE4 +/+ /FAD +/− ) relative to E4FAD-(non-carrier; APOE4
suggesting NP1 is modulated by Aβ expression. Finally, relative to normal elderly, plasma NP1 was also elevated in patients with mild cognitive impairment (MCI) and elevated further in the subset who progressed to earlystage AD. In those patients, there was a trend towards increased NP1 levels in APOE4 carriers relative to noncarriers. These findings indicate that NP1 may represent a potential synapse-derived plasma biomarker relevant to early alterations in excitatory synapses in MCI and early-stage AD.
Introduction
Synaptic degeneration is one of the earliest pathological hallmarks of Alzheimer disease (AD). Synapse loss, not Aβ burden, is the major correlate of cognitive impairment and disease progression (Terry et al., 1991) . Thus therapeutic strategies for AD should include synapse-protective interventions (Shankar et al., 2007) but synaptic degeneration cannot be directly monitored. Overwhelming evidence supports the idea that soluble oligomeric Aβ (oAβ) represents the major Aβ toxic species that contributes to early synaptic and cognitive deficits in AD (Ma et al., 2006; Shankar et al., 2007; Gong and Iqbal, 2008; Tomic et al., 2009; Danysz and Parsons, 2012; Ma et al., 2013) , involving both NMDA receptor dysregulation (Guntupalli et al., 2016) and NMDA receptor-induced excitotoxicity (Snyder et al., 2005; Shankar et al., 2007; Li et al., 2011) .
The APOE4 allele is the most common genetic risk factor for AD. It increases AD risk by 4-15 fold and is present in more than half of all patients with MCI or dementia due to AD (Bu, 2009; Hua et al., 2011) . Human APOE4 accelerates amyloid deposition, reduces amyloid clearance and glucose uptake, and stabilizes oAβ. Since clinical symptoms of
